A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
一项评估奥特妥珠单抗（一种抗CD37单特异性ADAPTIR治疗蛋白）在慢性淋巴细胞白血病中安全性和耐受性的I期研究
期刊:Blood
影响因子:23.1
doi:10.1182/blood-2013-07-512137
Byrd, John C; Pagel, John M; Awan, Farrukh T; Forero, Andres; Flinn, Ian W; Deauna-Limayo, Delva P; Spurgeon, Stephen E; Andritsos, Leslie A; Gopal, Ajay K; Leonard, John P; Eisenfeld, Amy J; Bannink, Jeannette E; Stromatt, Scott C; Furman, Richard R
